Zydus Cadila Group could make history after applying for approval for the first ever human DNA vaccine in India. But that could be just the start for a technology that could treat a vast array of diseases, including cancer, infectious diseases and chronic diseases.
The world has been running an ultramarathon since the COVID-19 pandemic began, but despite the ups and downs of cases and deaths, the wins and losses of clinical efforts, every day is another step forward toward herd immunity and the finish line.
Although 14 of the 17 stocks that make up BioWorld’s Neurological Disease Index (NDI) dropped in value over the last month, the index is still ahead by about 9% this year, with a huge surge by Prothena Corp. plc leading the way.
For the first time this year, BioWorld’s Biopharmaceutical Index is showing signs of life with an increase of 5.6%, boosted primarily by Alzheimer’s disease efforts from Biogen Inc. and Eli Lilly and Co. Biogen’s stock (NASDAQ:BIIB) is up about 36.4% this year and has been front and center due to its controversial FDA approval for Aduhelm (aducanumab) in June. Lilly’s stock (NYSE:LLY) has climbed by more than 44%, and it was granted breakthrough therapy designation a month ago for its Alzheimer’s candidate donanemab.
RSS
